funding availability
Whether the company can raise money when it needs it, by equity, debt or refinancing, and on what terms.
Exposure · 55 companies
ADBT Advasa Holdings, Inc.
Exposed“Their renewal, replacement, expansion and pricing are uncertain; market disruption, higher rates, inflation, regulation or industry developments could reduce availability or increase costs.”
- Revenue$2.2BYoY +17.3%
- Net income$426.3MYoY +14.8%
APMD Apnimed, Inc.
Exposed“APMD expects significant losses to continue and says there is substantial doubt about its ability to continue as a going concern.”
ARCC ARES CAPITAL CORP
Exposed“These conditions have materially affected—and could continue to affect—portfolio values and the company’s ability to raise or deploy capital.”
- Total investment income$763.0MYoY −2.4%
- Net income$319.0MYoY −21.0%
ARMP Armata Pharmaceuticals, Inc.
Exposed“The company needs substantial additional capital to operate and develop products; financing may be unavailable or offered only on unfavorable terms.”
- Revenue$4.9MYoY −5.2%
- Net income−$173.8Mvs −$18.9M year ago
- Revenue$3.2MYoY +173.6%
- Net income$54.9Mvs −$26.7M year ago
ASPE Aspen Neuroscience, Inc.
Exposed“Additional capital will be needed; unavailable or unfavorable financing could dilute shareholders, impose restrictive terms, require relinquishing valuable rights, or force delays, reductions or termination of programs.”
BBTX Bambusa Therapeutics, Inc.
Exposed“Management concluded there is substantial doubt about the company’s ability to continue as a going concern for the 12 months after the audited financial statements were available to be issued.”
BE Bloom Energy Corp
Exposed“Management expects cash and operating cash generation to cover at least 12 months of anticipated needs, but warns that future financing may be needed and could be unavailable, restrictive or dilutive.”
- Revenue$1.2BYoY +138.1%
- Net income$250.3Mvs −$23.1M year ago
BLSM BlossomHill Therapeutics, Inc.
Exposed“The company expects to need substantial additional financing; unavailable or unfavorable funding could dilute stockholders or delay, reduce, or terminate development programs.”
BRVE Braveheart Bio, Inc.
Exposed“Financing may be unavailable, costly or dilutive, and failure to raise funds could force it to delay, reduce or terminate development, surrender rights, or cease operations.”
BX Blackstone Group
Exposed“Liquidity depends partly on realizations, which can be volatile, and may be pressured if weak realizations coincide with fund capital calls.”
- Revenue$3.1BYoY −0.8%
- Net income$662.4MYoY +6.0%
CAPR CAPRICOR THERAPEUTICS, INC.
Exposed“It expects to need additional capital to fund clinical trials and development programs.”
- Revenue$0vs $0 year ago
- Net income−$42.7MYoY −73.6%
CBOE Cboe Global Markets, Inc.
Exposed“Cboe Clear Europe also has a €1.20 billion secured facility expected to terminate within a year; replacement financing and the facility’s ability to cover clearing obligations are material liquidity risks.”
- Revenue$1.4BYoY +19.0%
- Net income$428.2MYoY +42.4%
CIM CHIMERA INVESTMENT CORP
Exposed“Much of this funding is short-term, uncommitted, and renewable at lenders’ discretion.”
- Net interest income$266.4MYoY +0.7%
- Net income$230.5MYoY +30.9%
- Net interest income$71.2MYoY +9.5%
- Net income−$172.2Mvs −$580.0K year ago
CRWV CoreWeave, Inc.
Exposed“If cash flow or refinancing access is insufficient, the company may have to delay investment, sell assets, raise capital, or restructure debt.”
- Revenue$3.7BYoY +168.2%
- Net income−$709.0Mvs −$110.0M year ago
CSQR Csquare, Inc.
Exposed“Higher interest costs, capital requirements, and continued reliance on refinancing and capital-market access remain key risks.”
CTY CITY THERAPEUTICS, INC.
Exposed“The company has no committed additional financing and expects losses and expenses to rise; it may need capital before the stated runway ends.”
CVNA Carvana
Exposed“Management expects available sources to cover operations and commitments for at least 12 months, while longer-term debt service and growth investment depend on cash generation and continued access to financing.”
- Revenue$8.0BYoY +42.4%
- Net income$289.0MYoY +91.4%
EMI Encore Medical, Inc.
Exposed“Management plans to seek additional equity financing, but availability and sufficiency are uncertain.”
ENB Enbridge
Exposed“Enbridge identifies capital-market volatility as a potential funding constraint given its sizable growth program; it relies on operating cash flow, commercial paper, credit facilities and debt/equity offerings while seeking to preserve investment-grade ratings and diversified bank access.”
- RevenueC$21.1BYoY +44.0%
- Net incomeC$1.4BYoY +77.0%
EPD Enterprise Products
Exposed“Investment plans depend on cash generation and access to capital, and are exposed to commodity prices, demand, customer credit, costs, labor and materials availability, weather and regulation.”
- Revenue$17.9BYoY +49.3%
- Net income$1.6BYoY +21.4%
ETRA Electra Therapeutics, Inc.
Exposed“A funding shortfall could delay, reduce, or terminate programs.”
FFPP Fast Finance Pay Corp.
Exposed“Management states cash will not fund operations for one year after the prospectus date without additional fundraising and acknowledges substantial doubt about the company’s ability to continue as a going concern.”
GEV GE Vernova
Exposed“A below-investment-grade downgrade was estimated to have insignificant direct liquidity impact, but could raise financing and hedging costs, impair contract awards and credit access, and increase refinancing risk.”
- Revenue$12.6BYoY +26.8%
- Net income$1.3BYoY +185.6%
HE Hawaiian Electric Industries
Exposed“HEI is arranging financing for remaining settlement payments, but success is not assured; below-investment-grade ratings, rebuilding needs, inflation and fuel costs add funding pressure.”
- Revenue$1.0BYoY +27.6%
- Net income$35.5MYoY +13.6%
IAM Iambic Therapeutics, Inc.
Exposed“Additional capital will likely be needed; financing may dilute shareholders, impose restrictive terms, or require IAM to surrender valuable rights.”
IMC IMC Rare Earths Ltd
Exposed“Further financing will be needed for working capital and project development, and management cautions that it may not be successful in obtaining it.”
LIS LIS Technologies Inc
Exposed“We will need to raise substantial additional capital through one or more financing transactions, which may include equity or debt financings, strategic investments, commercial arrangements, or other sources of capital, to implement our longer-term business plan and advance our technology toward commercialization.”
LTGO Latigo Biotherapeutics, Inc.
Exposed“Financing may be unavailable, delayed, or unfavorable; equity could dilute holders, debt could impose restrictive terms, and collaborations or licenses could require surrendering valuable rights.”
LYCA Lycia Therapeutics, Inc.
Exposed“Further capital may be needed; unavailable or unfavorable financing could force delays, reductions or termination of programs.”
MAIN Main Street Capital Corp
Exposed“Access to debt and equity financing may also be unavailable or unattractive when needed.”
- Total investment income$566.4MYoY +4.7%
- Net income$493.4MYoY −2.9%
- Total investment income$142.5MYoY +1.9%
- Net income$117.1MYoY −5.3%
MRNA Moderna
Exposed“Moderna warns that operating cash flow may be insufficient to service debt and fund capital expenditures.”
- Revenue$1.3BYoY +29.2%
- Net income$162.0Mvs −$200.0M year ago
MSTR Strategy
Exposed“The company expects to rely on USD cash and reserves, bitcoin sales, at-the-market (ATM) sales of common and preferred stock, and additional debt or equity financing.”
- Revenue$125.4MYoY −2.5%
- Net income$19.5Bvs $2.8B year ago
NEE NextEra Energy
Exposed“NEE, FPL, and NEECH depend on operating cash flow and capital-market access; a downgrade could increase funding costs, restrict financing access, or trigger collateral requirements.”
- Revenue$8.1BYoY +1.6%
- Net income$4.8BYoY +95.9%
NEOA Neo Aeronautics, Inc.
Exposed“Capital may be unavailable or costly; shortfalls could force dilution, debt-service burdens, restrictions, spending cuts, delayed plans, restructuring, or curtailed or ceased operations.”
NUOX NuvOx Therapeutics, Inc.
Exposed“Financing may be unavailable or costly: equity dilutes shareholders, debt adds repayment and covenant burdens, and collaborations may require surrendering rights or future revenue.”
QMLS QumulusAI, Inc.
Exposed“Financing may be unavailable or costly, potentially delaying expansion or requiring reduced investment, asset sales, or restructuring.”
QS QuantumScape
Exposed“Additional capital will likely be needed, but financing may be unavailable or costly; equity issuance could dilute holders, and registered shares and awards may add selling pressure.”
- Revenue—
- Net income−$84.5MYoY +20.2%
RZAI ROZE AI INC.
Exposed“Additional equity or debt funding may be needed, and financing on acceptable terms is not assured; inability to raise funds could impair growth, debt repayment, or continued operations.”
RZRA Rezera Inc.
Exposed“Financing may be unavailable or unfavorable; equity can dilute holders, debt can add fixed payments and restrictive covenants, and partnerships may require surrendering valuable rights.”
SBE SB Energy, Inc.
Exposed“The realization of that capacity and backlog is linked to the timely development and commissioning of the generation facilities and to the announced Partnership funding.”
SCTX Scribe Therapeutics, Inc.
Exposed“The company will require significant additional capital for research, trials, manufacturing and potential commercialization.”
SEQC SeeQC, Inc.
Exposed“Funding depends on executing its operating plan and obtaining capital that may be unavailable, costly, dilutive, or subject to restrictive terms.”
SMR NuScale
Exposed“continued operating cash burn and reliance on equity-market access remain significant funding and dilution risks.”
- Revenue$31.5MYoY −15.0%
- Net income−$355.8MYoY −160.4%
- Revenue$281.0KYoY −96.6%
- Net income−$43.7MYoY +84.0%
SO Southern Company
Exposed“Environmental rules affecting coal combustion residuals and greenhouse-gas emissions, capital-cost recovery, affordability, fuel and labor costs, weather, customer credit and access to capital remain material uncertainties.”
- Revenue$8.8BYoY +13.0%
- Net income$2.0BYoY +19.6%
SPG Simon Property Group
Exposed“Liquidity is considered sufficient for debt maturities and capital needs through 2026–27, but a prolonged capital-market disruption or weaker operating cash flow could require additional borrowing, reduced capital spending, or other financing.”
- Revenue$1.8BYoY +13.3%
- Net income$499.8MYoY −17.7%
STA Starton Holdings, Inc.
Exposed“The company expects to need substantial additional capital to advance development, obtain approvals and potentially commercialize products; financing may be unavailable, costly or dilutive.”
TGT Target Corporation
Exposed“Target also warned that a credit-rating downgrade or adverse market conditions could restrict debt-market access or raise financing costs.”
- Revenue$26.5BYoY +5.3%
- Net income$1.9BYoY +100.7%
UPST Upstart Holdings
Exposed“If marketplace funding is insufficient, Upstart may need to hold more loans, accept less favorable financing or reduce originations.”
- Revenue$1.0BYoY +64.0%
- Net income$53.6Mvs −$128.6M year ago
- Revenue$370.5MYoY +33.7%
- Net income$36.6MYoY +15.0%
VRHI Veri MedTech Holdings, Inc.
Exposed“Continued operations depend on executing the business plan, generating sufficient revenue, and raising capital as needed.”
WBD Warner Bros. DiscoveryDelisted
Exposed“Management expects cash, operating cash generation and available credit to meet needs for the next 12 months, but substantial debt service, content and sports-rights investment, and credit ratings and leverage constrain financial flexibility.”
- Revenue$8.7BYoY −11.2%
- Net income$149.0MYoY −90.6%
WELL Welltower
Exposed“Reliance on external funding also exposes the strategy to capital-market availability and financing costs.”
- Revenue$3.7BYoY +38.4%
- Net income$396.6MYoY +41.4%
WWB WINDWARD BIO GROUP AG
Exposed“Further capital will be needed; unavailable or unfavorable financing could force delays, reductions, or termination of programs.”
No companies have a recent 8-K matching these events.
No companies in the selected roles.